BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 32158625)

  • 1. A
    Xu F; Lin H; He P; He L; Chen J; Lin L; Chen Y
    Oncoimmunology; 2020; 9(1):1731943. PubMed ID: 32158625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
    Front Immunol; 2020; 11():590618. PubMed ID: 33391264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma.
    Zhai W; Chen S; Duan F; Wang J; Zhao Z; Lin Y; Rao B; Wang Y; Zheng L; Long H
    Cancer Med; 2023 Feb; 12(4):4968-4980. PubMed ID: 36056909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
    Zhou W; Zhang W
    BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
    BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer.
    Zhang F; Zhong W; Li H; Huang K; Yu M; Liu Y
    Front Cell Dev Biol; 2021; 9():665265. PubMed ID: 34124046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.
    Miao TW; Yang DQ; Chen FY; Zhu Q; Chen X
    Biosci Rep; 2022 Aug; 42(8):. PubMed ID: 35866375
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhao L; Qu X; Wu Z; Li Y; Zhang X; Guo W
    Aging (Albany NY); 2020 Jul; 12(14):14556-14568. PubMed ID: 32694238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.